Kevin Outterson | Profiles RNS

Kevin Outterson, JD, LLM

Professor of Law and N. Neal Pike Scholar

Boston University School of Law

Dept of Health and Disability Law

LLM, University of Cambridge
JD, Northwestern University School of Law

Websites

Boston University School of Law Profile

Research interests in pharmaceutical innovation, including the law & economics of antimicrobial resistance.

Associate Professor of Health Law, Ethics & Human Rights
Boston University School of Public Health
Health Law, Policy & Management
Center for Health Law, Ethics & Human Rights

Executive Director
Boston University School of Law
Combating Antibiotic Resistant Bacteria Biopharmaceutical Accelerator (CARB-X)

BU Sponsored Research

ACCELERATING THE DEVELOPMENT OFINNOVATIVE PREVENTIVE APPROACHES TO COMBAT AMR
05/18/2018 - 05/31/2022 (PI)
Bill and Melinda Gates Foundation

CARB-X/ UK GAMRIF
05/18/2018 - 03/31/2022 (PI)
Department of Health and Social Care

WT CARB-X PD COSTS COST-SHARE
04/01/2017 - 07/31/2021 (PI)
Wellcome Trust

WT CARB-X NON AWARDEE COSTS
04/01/2017 - 07/31/2021 (PI)
Wellcome Trust

CARB-X
08/01/2016 - 07/31/2021 (PI)
HHS/Assistant Secretary for Preparedness and Response
5 IDSEP160030-03-00

Yr	Title	Project-Sub Proj	Pubs

Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.

Kållberg C, Årdal C, Salvesen Blix H, Klein E, M Martinez E, Lindbæk M, Outterson K, Røttingen JA, Laxminarayan R. Introduction and geographic availability of new antibiotics approved between 1999 and 2014. PLoS One. 2018; 13(10):e0205166. PMID: 30325963.
Bhatti T, Lum K, Holland S, Sassman S, Findlay D, Outterson K. A Perspective on Incentives for Novel Inpatient Antibiotics: No One-Size-Fits-All. J Law Med Ethics. 2018 Jun; 46(1_suppl):59-65. PMID: 30146959.
Årdal C, Baraldi E, Theuretzbacher U, Outterson K, Plahte J, Ciabuschi F, Røttingen JA. Insights into early stage of antibiotic development in small- and medium-sized enterprises: a survey of targets, costs, and durations. J Pharm Policy Pract. 2018; 11:8. PMID: 29632669.
Tacconelli E, Carrara E, Savoldi A, Harbarth S, Mendelson M, Monnet DL, Pulcini C, Kahlmeter G, Kluytmans J, Carmeli Y, Ouellette M, Outterson K, Patel J, Cavaleri M, Cox EM, Houchens CR, Grayson ML, Hansen P, Singh N, Theuretzbacher U, Magrini N. Discovery, research, and development of new antibiotics: the WHO priority list of antibiotic-resistant bacteria and tuberculosis. Lancet Infect Dis. 2018 Mar; 18(3):318-327. PMID: 29276051.
Theuretzbacher U, Savic M, Årdal C, Outterson K. Market watch: Innovation in the preclinical antibiotic pipeline. Nat Rev Drug Discov. 2017 Nov; 16(11):744-745. PMID: 28983100.
Barlam TF, Morgan JR, Kaplan WA, Outterson K, Pelton SI. Disproportionate Exposure to Antibiotics in Children at Risk for Invasive Pneumococcal Disease: Potential for Emerging Resistance and Opportunity for Antibiotic Stewardship. J Pediatric Infect Dis Soc. 2017 Sep 07.View Related Profiles.
Morgan, Jake
Outterson, Kevin
Pelton, Stephen
Barlam, Tamar
Kaplan, Warren
PMID: 28992176.
Årdal C, Baraldi E, Ciabuschi F, Outterson K, Rex JH, Piddock LJV, Findlay D. To the G20: incentivising antibacterial research and development. Lancet Infect Dis. 2017 08; 17(8):799-801. PMID: 28689703.
Deak D, Powers JH, Outterson K, Kesselheim AS. The Fight Against Multidrug-Resistant Bacteria. Ann Intern Med. 2017 01 03; 166(1):79. PMID: 28030672; DOI: 10.7326/L16-0582;.
Outterson K, McDonnell A. Antimicrobial Resistance: The Authors Reply. Health Aff (Millwood). 2016 10 01; 35(10):1936. PMID: 27702975.
Outterson K, Rex JH, Jinks T, Jackson P, Hallinan J, Karp S, Hung DT, Franceschi F, Merkeley T, Houchens C, Dixon DM, Kurilla MG, Aurigemma R, Larsen J. Accelerating global innovation to address antibacterial resistance: introducing CARB-X. Nat Rev Drug Discov. 2016 09; 15(9):589-90. PMID: 27469032; DOI: 10.1038/nrd.2016.155;.

Showing 10 of 66 results. Show More

Outterson K, Gopinathan U, Clift C, So AD, Morel CM, Røttingen JA. Delinking Investment in Antibiotic Research and Development from Sales Revenues: The Challenges of Transforming a Promising Idea into Reality. PLoS Med. 2016 Jun; 13(6):e1002043. PMID: 27299990; PMCID: PMC4907461; DOI: 10.1371/journal.pmed.1002043;.
Deak D, Outterson K, Powers JH, Kesselheim AS. Progress in the Fight Against Multidrug-Resistant Bacteria? A Review of U.S. Food and Drug Administration-Approved Antibiotics, 2010-2015. Ann Intern Med. 2016 Sep 06; 165(5):363-72. PMID: 27239977; DOI: 10.7326/M16-0291;.
Outterson K, McDonnell A. Funding Antibiotic Innovation With Vouchers: Recommendations On How To Strengthen A Flawed Incentive Policy. Health Aff (Millwood). 2016 May 01; 35(5):784-90. PMID: 27140983; DOI: 10.1377/hlthaff.2015.1139;.
Rex JH, Outterson K. Antibiotic reimbursement in a model delinked from sales: a benchmark-based worldwide approach. Lancet Infect Dis. 2016 Apr; 16(4):500-5. PMID: 27036356; DOI: 10.1016/S1473-3099(15)00500-9;.
Årdal C, Outterson K, Hoffman SJ, Ghafur A, Sharland M, Ranganathan N, Smith R, Zorzet A, Cohn J, Pittet D, Daulaire N, Morel C, Rizvi Z, Balasegaram M, Dar OA, Heymann DL, Holmes AH, Moore LS, Laxminarayan R, Mendelson M, Røttingen JA. International cooperation to improve access to and sustain effectiveness of antimicrobials. Lancet. 2016 Jan 16; 387(10015):296-307. PMID: 26603920; DOI: 10.1016/S0140-6736(15)00470-5;.
Outterson K, Powers JH, Daniel GW, McClellan MB. Repairing the broken market for antibiotic innovation. Health Aff (Millwood). 2015 Feb; 34(2):277-85. PMID: 25646108; DOI: 10.1377/hlthaff.2014.1003;.
Hoffman SJ, Outterson K, Røttingen JA, Cars O, Clift C, Rizvi Z, Rotberg F, Tomson G, Zorzet A. An international legal framework to address antimicrobial resistance. Bull World Health Organ. 2015 Feb 01; 93(2):66. PMID: 25883395; PMCID: PMC4339972; DOI: 10.2471/BLT.15.152710;.
Hoffman SJ, Outterson K. What Will It Take to Address the Global Threat of Antibiotic Resistance? J Law Med Ethics. 2015; 43(2):363-8. PMID: 26242959; DOI: 10.1111/jlme.12253;.
Hoffman SJ, Outterson K. INTRODUCTION: What Will It Take to Address the Global Threat of Antibiotic Resistance? J Law Med Ethics. 2015; 43 Suppl 3:6-11. PMID: 26243236; DOI: 10.1111/jlme.12267;.
Outterson K. Clinical trial transparency--antidote to weaker off-label-promotion rules? N Engl J Med. 2014 Jul 3; 371(1):1-3. PMID: 24988551; DOI: 10.1056/NEJMp1402969;.
Outterson K. The Drug Quality and Security Act--mind the gaps. N Engl J Med. 2014 Jan 9; 370(2):97-9. PMID: 24369048; DOI: 10.1056/NEJMp1314691;.
Outterson K, Powers JH, Seoane-Vazquez E, Rodriguez-Monguio R, Kesselheim AS. Approval and withdrawal of new antibiotics and other antiinfectives in the U.S., 1980-2009. J Law Med Ethics. 2013; 41(3):688-96. PMID: 24088160; DOI: 10.1111/jlme.12079;.
Outterson K. Regulating compounding pharmacies after NECC. N Engl J Med. 2012 Nov 22; 367(21):1969-72. PMID: 23134357; DOI: 10.1056/NEJMp1212667;.
Outterson K. Punishing health care fraud--is the GSK settlement sufficient? N Engl J Med. 2012 Sep 20; 367(12):1082-5. PMID: 22970920.
Huberfeld N, Leonard EW, Outterson K. Plunging into Endless Difficulties: Medicaid and Coercion in the Healthcare Cases. SSRN Electronic Journal. 2012. View Publication
Outterson K. Smoking and the First Amendment. N Engl J Med. 2011 Dec 22; 365(25):2351-3. PMID: 22149735; DOI: 10.1056/NEJMp1113011;.
Outterson K. Higher First Amendment hurdles for public health regulation. N Engl J Med. 2011 Aug 18; 365(7):e13. PMID: 21812665; DOI: 10.1056/NEJMp1107614;.
Outterson K, Pogge T, Hollis A. Combating Antibiotic Resistance Through the Health Impact Fund. SSRN Electronic Journal. 2011. View Publication
Frakt A, Outterson K. After the Deluge: Health Reform Without an Individual Mandate. 2011.
Selinger E, Outterson K, Whyte KP. Poverty Tourism, Justice and Policy. Public Integrity. 2011; 14(1). View Publication
Outterson K, Yevtukhova O. Germ Shed Management in the United States. 2011. View Publication
So AD, Gupta N, Brahmachari SK, Chopra I, Munos B, Nathan C, Outterson K, Paccaud JP, Payne DJ, Peeling RW, Spigelman M, Weigelt J. Towards new business models for R&D for novel antibiotics. Drug Resist Updat. 2011 Apr; 14(2):88-94. PMID: 21439891; DOI: 10.1016/j.drup.2011.01.006;.
Outterson K, Orentlicher D, Robertson C, Pasquale FA. William H. Sorrell, Attorney General of Vermont, et al. v. IMS Health Inc., et al. - Amicus Brief in Support of Petitioners. SSRN Publication Journal. 2011. View Publication
Kesselheim AS, Outterson K. Improving antibiotic markets for long-term sustainability. Yale J Health Policy Law Ethics. 2011; 11(1):101-67. PMID: 21381513.
Whyte KP, Selinger E, Outterson K. Poverty Tourism and the Problem of Consent . Journal of Global Ethics. 2010; 7(3). View Publication
Outterson K. Death from the Public Domain?. Texas Law Review. 2010; 87.
Outterson K, Powers JH, Gould IM, Kesselheim AS. Questions about the 10 x '20 Initiative. Clin Infect Dis. 2010 Sep 15; 51(6):751-2; author reply 754-5. PMID: 20731566; DOI: 10.1086/655955;.
Kesselheim AS, Outterson K. Fighting antibiotic resistance: marrying new financial incentives to meeting public health goals. Health Aff (Millwood). 2010 Sep; 29(9):1689-96. PMID: 20820028; DOI: 10.1377/hlthaff.2009.0439;.
Outterson K, Light DW. Blackwell Companions to Philosophy (Kuhse H, Singer P, eds.). A Companion to Bioethics, Second Edition. 2010; 417-429. View Publication
Outterson K. The Legal Ecology of Resistance: The Role of Antibiotic Resistance in Pharmaceutical Innovation. Cardozo Law Review. 2009.
Outterson K, Kesselheim AS. How Medicare could get better prices on prescription drugs. Health Aff (Millwood). 2009 Sep-Oct; 28(5):w832-41. PMID: 19643778; DOI: 10.1377/hlthaff.28.5.w832;.
Outterson K, Selinger E. The Ethics of Poverty Tourism. Environmental Philosophy. 2009; 7(2):93-113. View Publication
Outterson K. Research Handbook on Intellectual Property Law and the WTO ( Carlos C, ed.). Disease-Based Limitations on Compulsory Licenses Under Articles 31 and 31 bis. 2009. View Publication
Outterson K. The End of Reparations Talk? - Reparations in an Obama World. Kansas Law Review. 2009; 57:935.
Outterson K. Import Safety: Regulatory Governance in the Global Economy (Coglianese C, Finkel A, Zaring S, eds.). Import Safety Rules And Generic Drug Markets. 2009. View Publication
Outterson K. Introduction: pharmaceutical innovation: law & the public's health. J Law Med Ethics. 2009; 37(2):173-5. PMID: 19493064; DOI: 10.1111/j.1748-720X.2009.00363.x;.
Outterson K. Foreword--Will HPV vaccines prevent cervical cancers among poor women of color?: global health policy at the intersection of human rights and intellectual property law. Am J Law Med. 2009; 35(2-3):247-52. PMID: 19697748.
Outterson K. Antibiotic Resistance and Antibiotic Development - Author’s Reply. Lancet Infectious Diseases. 2008; 8(4):212-214. View Publication
Outterson K. Should access to medicines and TRIPS flexibilities be limited to specific diseases? Am J Law Med. 2008; 34(2-3):279-301. PMID: 18697695.
Outterson K, Kesselheim AS. Market-based licensing for HPV vaccines in developing countries. Health Aff (Millwood). 2008 Jan-Feb; 27(1):130-9. PMID: 18180488; DOI: 10.1377/hlthaff.27.1.130;.
Outterson K, Samora JB, Keller-Cuda K. Will longer antimicrobial patents improve global public health? Lancet Infect Dis. 2007 Aug; 7(8):559-66. PMID: 17646029.
Outterson K. Access to Global Disease Innovation. WHO Inter Governmental Working Group. 2006. View Publication
Outterson K, Smith R. Counterfeit Drugs: The Good, the Bad and the Ugly. Albany Law Journal of Science and Technology. 2006; 16(3):525.
Outterson K. The Power Of Pills: Social, Ethical and Legal Issues in Drug Development, Marketing and Pricing (Cohen J, Illingworth P, Schuklenk U, eds.). Fair Followers: Expanding Access To Generic Pharmaceuticals For Low- and Medium Income Populations. 2006.
Outterson K. Patent buy-outs for global disease innovations for low- and middle-income countries. Am J Law Med. 2006; 32(2-3):159-73. PMID: 16927608.
Outterson K. Agony in the Antipodes: The Generic Drug Provisions of the Australia-USA Free Trade Agreement. Journal of Generic Medicines. 2005; 2(4):316-326. View Publication
Outterson K. The Vanishing Public Domain: Antibiotic Resistance, Pharmaceutical Innovation and Intellectual Property Law. University of Pittsburgh Law Review. 2005; 67:67-123. View Publication
Outterson K. US Senate Health, Education, Labor, & Pensions Committee Hearing on Drug Importation - Response to Dean Arnold. SSRN Electronic Journal. 2005. View Publication
Outterson K. Nonrival Access to Pharmaceutical Knowledge. SSRN Electronic Journal. 2005. View Publication
Outterson K. The Vanishing Public Domain: Antibiotic Resistance, Pharmaceutical Innovation and Intellectual Property Law. University of Pittsburgh Law Review . 2005; 67:67-123.
Outterson K. The Vanishing Public Domain: Antibiotic Resistance, Pharmaceutical Innovation and Global Public Health . University of Pittsburgh Law Review . 2005; 67:67-123.
Outterson K. Pharmaceutical arbitrage: balancing access and innovation in international prescription drug markets. Yale J Health Policy Law Ethics. 2005; 5(1):193-291. PMID: 15742578.
Outterson K. Tragedy and remedy: reparations for disparities in black health. DePaul J Health Care Law. 2005; 9(1):735-91. PMID: 17061385.
Outterson K. Resolving Dysfunctional Pharmaceutical Arbitrage and Counterfeiting through the Proposed Hubbard-Love R&D Treaty. SSRN Electronic Journal. 2004. View Publication
Outterson K. Slave taxes. Should America Pay?: Slavery and the Raging Debate over Reparations (Winbush R, ed.). 2003.
Outterson K, Butler JL. Disease management: legal strategies for the next generation of managed care. J Health Law. 1998; 31(3):291-314. PMID: 10620832.

This graph shows the total number of publications by year, by first, middle/unknown, or last author.

Bar chart showing 66 publications over 17 distinct years, with a maximum of 9 publications in 2011